Table 2.
The cell survival values and in vitro cytotoxicity of 13a–13e in three different cancer cell lines [35].
| Compound | CS Values [%] (Mean ± SD) a | IC50 [μM] (Mean ± SD) b | ||||
|---|---|---|---|---|---|---|
| HepG2 c | LU-1 d | RD e | HepG2 c | LU-1 d | RD e | |
| 13a | 68.42 ± 0.96 | 29.61 ± 0.15 | 66.79 ± 1.51 | >100 ± 1.45 | 7.04 ± 0.64 | >100 ± 1.16 |
| 13b | 45.98 ± 1.45 | 25.11 ± 1.54 | 72.81 ± 1.56 | 7.21 ± 0.60 | 4.56 ± 0.18 | >100 ± 0.65 |
| 13c | 59.88 ± 1.80 | 65.52 ± 2.53 | 64.52 ± 1.34 | >100 ± 1.80 | >100 ± 0.84 | >100 ± 0.35 |
| 13d | 37.20 ± 2.30 | 15.12 ± 0.60 | 70.00 ± 2.19 | 5.36 ± 0.47 | 2.85 ± 0.20 | >100 ± 1.42 |
| 13e | 98.28 ± 0.95 | 78.70 ± 1.15 | 98.42 ± 1.47 | >100 ± 1.36 | >100 ± 1.34 | >100 ± 1.89 |
| ellipticine f | 1.25 ± 0.30 | 1.87 ± 0.20 | 0 | 1.22 ± 0.09 | 1.30 ± 0.10 | 1.18 ± 0.08 |
a The concentration of the sample c = 5 µg · mL−1. CS (cell survival) value [%] is the ability of cells to survive at a certain concentration of the reagent [in %] compared with the control (n = 3); b Data are presented as means of the concentration of the sample required for 50% inhibition of cell growth ± SD from triplicated; c HepG2 (human hepatocellular carcinoma); d LU-1 (human lung adenocarcinoma); e RD (human rhabdomyosarcoma); f ellipticine (5,11-dimethyl-6H-pyrido [4,3-b]carbazole) was used as a positive control.